Else Marit Inderberg

  • Head of Immunomonitoring; PhD
  • +47 22 78 23 17

Project leader

Education:

2008-2011: PhD in Tumour Immunology (Faculty of Medicine,University of Oslo, Norway) “Cancer vaccines and cancer-specific T-cell receptors; Development of novel immunotherapies”

2002-2005 : Diplôme EPHE Immunology (L’Ecole Pratique des Hautes Etudes, Sorbonne, Paris, France) «Development of an inducible melanoma model expressing a defined tumour antigen and its immunological characterisation »

1996-1998: BSc (Honours) Biochemistry University of Reading, UK

 

Research interests/projects:

Immunomonitoring facility for verification of treatment effects and mechanisms as well as biomarker discovery and development of novel immunotherapies

    • Detection of immune responses in patient samples pre- and post immunotherapy treatment.
    • Detection and discovery of immunotherapy biomarkers
    • Therapeutic TCR discovery and pre-clinical validation
    • Chimeric Antigen Receptors (CAR) discovery and pre-clinical validation
    • Discovery and pre-clinical validation of vaccination targets
    • Development of novel technologies to improve cell-based therapy

Work experience

2013-present:             Head of Immunomonitoring and Postdoctoral Fellow, Dept. of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway          

2011-2012:      Research Fellow,  Institute for Cancer Research, OUS- Radiumhospitalet, Norway

2008-2011:      PhD student, Section for Immunotherapy, Institute for Cancer Research, OUS- Radiumhospitalet, Norway

2005–2008:     Research assistant, Dept. of Immunology, Institute for Cancer Research, OUS-Radiumhospitalet, Oslo, Norway

2002- 2005:     Research assistant, Centre of Immunology Marseille-Luminy, France

2001- 2002:     Research assistant, Institute for Cancer Research, Radiumhospitalet, Norway

1999- 2001:     Research Assistant/Laboratory manager   Dept. of Immunology, Rayne Institute, King’s College School of Medicine, London, UK 

Awards

  • F1000Research prize 2015 for outstanding presentation at PIVAC‐15 conference
  • Inven2 Innovation award 2014: "A universal killer-T cell for personalized medicine"

 

 

 

Publications 2019

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Köksal H, Müller E, Inderberg EM, Bruland Ø, Wälchli S (2019)
Treating osteosarcoma with CAR T cells
Scand J Immunol, 89 (3), e12741
DOI 10.1111/sji.12741, PubMed 30549299

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S (2019)
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2019)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732

Theodossiou TA, Ali M, Grigalavicius M, Grallert B, Dillard P, Schink KO, Olsen CE, Wälchli S, Inderberg EM, Kubin A, Peng Q, Berg K (2019)
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy
NPJ Breast Cancer, 5, 13
DOI 10.1038/s41523-019-0108-8, PubMed 30993194

Publications 2018

Dillard P, Köksal H, Inderberg EM, Wälchli S (2018)
A Spheroid Killing Assay by CAR T Cells
J Vis Exp (142)
DOI 10.3791/58785, PubMed 30596389

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
J Hematol Oncol, 11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S (2017)
Human c-SRC kinase (CSK) overexpression makes T cells dummy
Cancer Immunol Immunother, 67 (4), 525-536
DOI 10.1007/s00262-017-2105-9, PubMed 29248956

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Oncoimmunology, 6 (4), e1302631
DOI 10.1080/2162402X.2017.1302631, PubMed 28507809

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Clin Cancer Res, 24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
Cancer Immunol Immunother, 66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S (2017)
A TCR-based Chimeric Antigen Receptor
Sci Rep, 7 (1), 10713
DOI 10.1038/s41598-017-11126-y, PubMed 28878363

Publications 2016

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Publications 2015

Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098

Publications 2014

Schiavelli R, Bonaventura R, Rial MC, Petrone H, Pujol GS, Gaite LJ, Acosta M, Gutierrez A, Acosta F, Valdez G, Raffaele P, Chanta G, Perez M, Potes L, Suso E, Cremades G, Ibañez J, Imperiali N, Luxardo R, Castellanos M, Maggiora E, Carreño CA, Cobos M, Marinic K, Sinchi JL et al. (2014)
First epidemiologic study in Argentina of the prevalence of BK viruria in kidney transplant patients
Transplant Proc, 46 (9), 3010-4
DOI 10.1016/j.transproceed.2014.07.009, PubMed 25420812

Publications 2013

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721

Publications 2012

Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012)
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
Oncoimmunology, 1 (5), 670-686
DOI 10.4161/onci.20426, PubMed 22934259

Publications 2011

Huijbers IJ, Soudja SM, Uyttenhove C, Buferne M, Inderberg-Suso EM, Colau D, Pilotte L, Powis de Tenbossche CG, Chomez P, Brasseur F, Schmitt-Verhulst AM, Van den Eynde BJ (2011)
Minimal tolerance to a tumor antigen encoded by a cancer-germline gene
J Immunol, 188 (1), 111-21
DOI 10.4049/jimmunol.1002612, PubMed 22140254

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Cancer Immunol Immunother, 60 (6), 809-18
DOI 10.1007/s00262-011-0991-9, PubMed 21365467

Publications 2007

Shanker A, Verdeil G, Buferne M, Inderberg-Suso EM, Puthier D, Joly F, Nguyen C, Leserman L, Auphan-Anezin N, Schmitt-Verhulst AM (2007)
CD8 T cell help for innate antitumor immunity
J Immunol, 179 (10), 6651-62
DOI 10.4049/jimmunol.179.10.6651, PubMed 17982055

Publications 2006

Huijbers IJ, Krimpenfort P, Chomez P, van der Valk MA, Song JY, Inderberg-Suso EM, Schmitt-Verhulst AM, Berns A, Van den Eynde BJ (2006)
An inducible mouse model of melanoma expressing a defined tumor antigen
Cancer Res, 66 (6), 3278-86
DOI 10.1158/0008-5472.CAN-05-3216, PubMed 16540681

Publications 2003

Noble A, Leggat JA, Inderberg EM (2003)
CD8+ immunoregulatory cells in the graft-versus-host reaction: CD8 T cells activate dendritic cells to secrete interleukin-12/interleukin-18 and induce T helper 1 autoantibody
Immunology, 109 (4), 476-86
DOI 10.1046/j.1365-2567.2003.01687.x, PubMed 12871213

Page visits: 6112